CSPC Pharmaceutical Group Co., Ltd

CSPC Pharmaceutical Holdings Group Co., Ltd. is one of the leading companies in my country's pharmaceutical industry, with total assets of 32 billion yuan and 22,000 employees. The company listed in Hong Kong (01093.HK) has a market value of more than HK$150 billion. It is a component stock of the Hong Kong Hang Seng Index and the first pharmaceutical stock in the 50 years since the Hang Seng Index was compiled. CSPC Pharmaceutical Group is mainly engaged in the development, production and sales of pharmaceutical products. The products mainly include nearly 1,000 varieties in seven series including cardiovascular and cerebrovascular, antibiotics, vitamins, antipyretics and analgesics, digestive system drugs, and anti-tumor drugs. There are 30 products with single product sales exceeding 100 million yuan, and product sales throughout the country and the world. More than 60 countries and regions. CSPC Pharmaceutical Group has been recognized as a "National Innovative Enterprise" by the Ministry of Science and Technology and other three ministries. It has the Central Institute of Materia Medica, a first-class high-tech drug incubation base in China, with more than 1,500 scientific researchers, including masters, doctors, returnee experts and other talents. With more than 1,000 employees, its new drug research and development capabilities rank among the top pharmaceutical companies in the country. Currently, the group has more than 200 new drug projects under development, including 40 large molecule drugs (biological products) and 30 small molecule drugs (chemically synthesized drugs), of which a total of 26 are in the clinical stage, mainly focusing on cardiovascular, cerebrovascular and metabolic diseases. (such as diabetes), tumors, psychiatry, neurological and other fields. "Enbipu", which has been launched on the market, is the world's leading drug in the field of stroke treatment. It is also my country's third Class I new drug with independent intellectual property rights and is protected by patents in 86 countries around the world. The research and development and rapid growth of innovative drugs such as Enbipu, Xuanning, Oulaining, Jinyouli, and Duomeisu have promoted the transformation and upgrading of CSPC Pharmaceutical Group. At present, preparation products have become the main source of profit, and the profit margin greatly exceeds that of traditional APIs. In order to pursue excellence and move towards high-end, CSPC Pharmaceutical Group continues to improve the connotation of product quality. Up to now, all the group’s drugs have passed the new version of GMP certification. In addition, a total of 16 CEP certificates and 33 DMF registration numbers have been obtained, and 21 products have successfully passed the US FDA on-site inspection. This marks that CSPC Pharmaceutical Group’s products have It can compete in foreign high-end markets, and solid preparations can be directly placed in pharmacies and counters in the United States. Currently, 8 varieties including tramadol hydrochloride tablets and benzonatate soft capsules have been sold in the United States, and the company's overall export delivery value has reached US$600 million. At the same time, CSPC Pharmaceutical Group has established an R&D laboratory in the United States, and a number of drugs are undergoing clinical trials in the United States. In the future, more new drug products will be launched in high-end international markets such as Europe and the United States. In the future, CSPC Pharmaceutical Group will continue to use "innovation" and "internationalization" as its two major driving engines, and gradually build itself into China's first "trillion-level" pharmaceutical company.